Brainstorm Cell Therapeutics (BCLI) Competitors $0.76 -0.01 (-1.04%) As of 09/4/2025 02:12 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCLI vs. DYAI, RNTX, MAAQ, RVPH, ITRM, KZR, CLSD, ASBP, CASI, and PMNShould you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Dyadic International (DYAI), Rein Therapeutics (RNTX), Mana Capital Acquisition (MAAQ), Reviva Pharmaceuticals (RVPH), Iterum Therapeutics (ITRM), Kezar Life Sciences (KZR), Clearside Biomedical (CLSD), Aspire Biopharma (ASBP), CASI Pharmaceuticals (CASI), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry. Brainstorm Cell Therapeutics vs. Its Competitors Dyadic International Rein Therapeutics Mana Capital Acquisition Reviva Pharmaceuticals Iterum Therapeutics Kezar Life Sciences Clearside Biomedical Aspire Biopharma CASI Pharmaceuticals Promis Neurosciences Dyadic International (NASDAQ:DYAI) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership. Is DYAI or BCLI more profitable? Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -134.84%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets Dyadic International-134.84% -355.39% -60.66% Brainstorm Cell Therapeutics N/A N/A -519.50% Which has higher valuation & earnings, DYAI or BCLI? Dyadic International has higher revenue and earnings than Brainstorm Cell Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyadic International$3.49M9.92-$5.81M-$0.19-5.04Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$3.10-0.25 Does the media prefer DYAI or BCLI? In the previous week, Dyadic International had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 2 mentions for Dyadic International and 1 mentions for Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 1.00 beat Dyadic International's score of 0.50 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Dyadic International Positive Brainstorm Cell Therapeutics Positive Which has more risk and volatility, DYAI or BCLI? Dyadic International has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Do analysts prefer DYAI or BCLI? Dyadic International presently has a consensus price target of $6.00, indicating a potential upside of 527.02%. Given Dyadic International's stronger consensus rating and higher probable upside, research analysts plainly believe Dyadic International is more favorable than Brainstorm Cell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders have more ownership in DYAI or BCLI? 28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 29.5% of Dyadic International shares are owned by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryDyadic International beats Brainstorm Cell Therapeutics on 11 of the 15 factors compared between the two stocks. Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCLI vs. The Competition Export to ExcelMetricBrainstorm Cell TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.41M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-0.2320.8975.7826.43Price / SalesN/A458.96546.96119.09Price / CashN/A44.5237.0558.92Price / Book-0.569.9311.146.06Net Income-$11.62M-$53.38M$3.29B$266.28M7 Day Performance0.40%0.63%0.16%-0.32%1 Month Performance31.40%6.31%6.26%3.44%1 Year Performance-81.66%11.63%54.63%23.11% Brainstorm Cell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCLIBrainstorm Cell Therapeutics2.466 of 5 stars$0.76-1.0%N/A-81.9%$8.41MN/A-0.2340Positive NewsShort Interest ↓DYAIDyadic International3.3025 of 5 stars$0.92+1.5%$6.00+551.3%-24.7%$33.34M$3.49M-4.857Short Interest ↓Gap DownRNTXRein TherapeuticsN/A$1.39+23.0%N/AN/A$32.39MN/A-0.529High Trading VolumeMAAQMana Capital AcquisitionN/A$3.81+0.5%N/A+1,078.8%$30.96MN/A0.001Gap DownRVPHReviva Pharmaceuticals2.3752 of 5 stars$0.45-2.2%$5.20+1,055.6%-64.3%$30.60MN/A-0.695ITRMIterum Therapeutics3.2254 of 5 stars$0.68-2.2%$9.00+1,229.8%-40.4%$30.22MN/A-0.8010News CoveragePositive NewsShort Interest ↓KZRKezar Life Sciences2.78 of 5 stars$3.95-0.5%$9.00+127.8%-32.4%$28.93M$7M-0.4160CLSDClearside Biomedical2.5268 of 5 stars$0.37-5.1%$4.20+1,042.9%-63.5%$28.85M$1.66M-0.9930Gap DownHigh Trading VolumeASBPAspire BiopharmaN/A$0.58+3.4%N/AN/A$28.49MN/A0.00N/ACASICASI Pharmaceuticals3.8504 of 5 stars$2.31-5.3%$4.00+73.2%-65.9%$28.41M$28.54M-0.80180News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionGap DownPMNPromis Neurosciences2.8023 of 5 stars$0.54+2.7%$4.33+702.6%-67.4%$27.97MN/A-2.575 Related Companies and Tools Related Companies DYAI Competitors RNTX Competitors MAAQ Competitors RVPH Competitors ITRM Competitors KZR Competitors CLSD Competitors ASBP Competitors CASI Competitors PMN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCLI) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCLI Stock Alerts